Decompensated Cirrhosis

Decompensated cirrhosis is the progression of chronic liver disease to life-threatening complications, requiring urgent management.

Definition and Epidemiology

• **Definition:** Decompensated cirrhosis is advanced liver disease marked by complications:

ascites, variceal bleeding, hepatic encephalopathy (HE), or jaundice. It indicates a decline

in liver synthetic function (e.g., ↓ albumin, ↑ INR).

- **Prevalence:** ~5-7% of cirrhosis patients decompensate yearly; 50% 5-year mortality post-decompensation.
- Risk Factors: Alcohol use, hepatitis B/C, NAFLD, male sex, age >50.
 - Pathophysiology:
 - Mechanisms: Cirrhosis causes portal hypertension (scarring → ↑ resistance) and liver
 dysfunction (↓ synthetic/metabolic capacity).
 - Decompensation:
 - Portal hypertension → Ascites, variceal bleeding, splenomegaly.
 - Liver failure → Jaundice (↑ bilirubin), coagulopathy (↑ INR), HE (↑ ammonia).
 - Systemic effects → Hepatorenal syndrome (HRS), infections (e.g., SBP).
 - Key Pathway: Splanchnic vasodilation (↑ NO) → ↓ effective arterial volume → RAAS activation → Renal vasoconstriction (HRS).

Causes and Precipitants

Category	Causes/Precipitants	Notes
Etiology	-Alcohol (40-50% of cases). -Hepatitis B/C. -NAFLD/NASH. -Autoimmune hepatitis.	Alcohol: Most common in U.S.; Hep C: Leading transplant indication.

Category	Causes/Precipitants	Notes
Precipitants	-Infection: SBP, pneumoniaGI Bleed: Variceal, non-varicealAlcohol binge: Worsens HE, triggers bleedMedications: Opioids, sedatives (↑ HE)Dehydration: Overdiuresis, diarrhea.	SBP: 10-30% mortality per episode.
Rare	- Wilson's disease (copper overload)Hemochromatosis (iron overload)Budd-Chiari syndrome (hepatic vein thrombosis).	Wilson's: Consider in young patients (<40 y/o).

MELD Score for Prognosis

MELD Score	Components	3-Month Mortality
<10	INR, bilirubin, creatinine	<2%
10-19	INR, bilirubin, creatinine	6-20%
20-29	INR, bilirubin, creatinine	20-50%
≥30	INR, bilirubin, creatinine	>50%

Clinical Presentation

Symptoms

- Ascites: Abdominal distension, discomfort.
- Variceal Bleed: Hematemesis, melena, shock.
- **HE:** Confusion, asterixis, coma (West Haven Grade I-IV).
- Jaundice: Yellowing of skin/eyes, dark urine.

• Exam:

- Spider angiomata, palmar erythema, gynecomastia (chronic liver disease).
- Ascites: Shifting dullness, fluid wave.
- **HE:** Asterixis, altered mental status.
- **Spleen:** Splenomegaly (portal hypertension).
- Complications: HRS, SBP, hepatopulmonary syndrome (hypoxemia).
- Substance Use: Alcohol binge → Worsens HE, triggers bleed.

Diagnostic Workup

· · Labs:

- **Liver Function:** ↑ Bilirubin (>3 mg/dL), ↓ albumin (<3.5 g/dL), ↑ INR (>1.5).
- **CBC:** Anemia (GI bleed), thrombocytopenia (splenomegaly).

- **Electrolytes:** Hyponatremia (HRS), ↑ creatinine (HRS).
- Ammonia: ↑ in HE (not always needed).
- Infection: Blood culture, paracentesis (SBP: PMN >250/μL).

Imaging:

- **Ultrasound:** Nodular liver, ascites, portal vein thrombosis.
- CT/MRI: Confirm cirrhosis, rule out HCC.
- Scoring Systems:
 - MELD (Model for End-Stage Liver Disease): Predicts 3-month mortality (see table).
 - Child-Pugh: Assesses severity (A-C; decompensated = B/C).
- Paracentesis: Diagnostic (SBP), therapeutic (large-volume for tense ascites).
- Key Tip: Always rule out infection (SBP) in decompensated cirrhosis with fever or worsening ascites.

Management Flowsheet: Decompensated Cirrhosis

- Step 1: Identify complication: Ascites, variceal bleed, HE, HRS.
- Step 2: Rule out infection: Paracentesis → SBP (PMN >250/µL) → Antibiotics (ceftriaxone 2 g IV q24h).
- Step 3: Manage complication:
 - Ascites: Na+ restriction (<2 g/day), diuretics (spironolactone 100 mg + furosemide 40 mg).
 - Variceal Bleed: Octreotide (50 mcg IV bolus, then 50 mcg/h), endoscopy (band ligation).
 - **HE:** Lactulose (titrate to 2-3 BM/day), rifaximin (550 mg BID).
 - HRS: Albumin (1 g/kg IV), midodrine (5-15 mg TID), octreotide (100-200 mcg
 SC TID).
- Step 4: Assess transplant candidacy: MELD score, sobriety (if alcohol-related).
- Step 5: Prevent recurrence: Beta-blockers (propranolol 20 mg BID) for varices, vaccinate (HAV, HBV).

Treatment

General Principles:

- Treat precipitant (e.g., stop alcohol, treat infection).
- Avoid hepatotoxic drugs (e.g., acetaminophen >2 g/day).
- Refer to hepatology for transplant evaluation (MELD >15).

Ascites:

- Na+ restriction (<2 g/day), spironolactone (100 mg daily), furosemide (40 mg
 - daily; 100:40 ratio).
- Large-volume paracentesis (>5 L) → Albumin (6-8 g/L removed).
- Variceal Bleed:
 - **Resuscitate:** 2 large-bore IVs, PRBCs (target Hgb 7-8 g/dL).
 - Octreotide (50 mcg IV bolus, then 50 mcg/h x 3-5 days).
 - **Endoscopy:** Band ligation or sclerotherapy.
 - **Antibiotics:** Ceftriaxone (1 g IV q24h x 7 days) for prophylaxis.
- Hepatic Encephalopathy (HE):
 - Lactulose (30 mL q2-4h until 2-3 BM/day, then titrate).
 - Rifaximin (550 mg BID) if refractory.
 - **Identify trigger:** Infection, GI bleed, constipation.
- Hepatorenal Syndrome (HRS):
 - Albumin (1 g/kg IV Day 1, then 20-40 g/day).
 - Vasoconstrictors: Midodrine (5-15 mg TID) + octreotide (100-200 mcg SC TID).
 - **Definitive:** Transplant.
- Spontaneous Bacterial Peritonitis (SBP):
 - Ceftriaxone (2 g IV q24h x 5-7 days).
 - Prophylaxis: Norfloxacin (400 mg daily) if prior SBP.
- Substance Use: Alcohol cessation (counseling, naltrexone 50 mg daily if sober), monitor

for withdrawal.

• Key Tip: Avoid over-transfusion in variceal bleed (↑ portal pressure); target Hgb
 7-8
 q/dL.

Examples

- Case 1: Variceal Bleed (Alcohol-Related Cirrhosis)
- **Presentation:** 55 y/o M, alcohol use, hematemesis, BP 90/60, Hgb 6.5 g/dL, INR 1.8, bilirubin 4 mg/dL.
- Interpretation: Decompensated cirrhosis (variceal bleed), MELD ~20 (20-50% 3-month mortality).
- Management: PRBCs (target Hgb 7-8 g/dL), octreotide (50 mcg/h IV), ceftriaxone (1 g IV), urgent endoscopy (band ligation), alcohol cessation.
- Case 2: Hepatorenal Syndrome (HRS)

- Presentation: 60 y/o F, cirrhosis (Hep C), ascites, SCr 2.8 (baseline 1.0), Na+ 128 mEq/L, no infection.
- Interpretation: HRS (↑ SCr, no other cause), Child-Pugh C (decompensated).
- Management: Albumin (1 g/kg IV), midodrine (10 mg TID), octreotide (100 mcg SC TID), hepatology referral for transplant.

Complications

- Short-Term: Variceal bleed, SBP, HE, HRS, HCC.
- Long-Term: Liver failure, portal vein thrombosis, 50% 5-year mortality.

Prognosis

- Mortality: 20-50% 1-year mortality post-decompensation; MELD >20 → High risk.
- Transplant: Only cure; MELD >15 → Consider listing.

Key Pearls

- • Decompensation = Ascites, variceal bleed, HE, or jaundice.
- •• Rule out SBP in worsening ascites (PMN >250/μL).
- MELD >15 → Refer for transplant evaluation.
- • Avoid hepatotoxins (e.g., acetaminophen >2 g/day).
- Alcohol cessation critical in substance use cases.

References

- • UpToDate: "Decompensated Cirrhosis" (2025).
- •• AASLD Guidelines: Cirrhosis Management (2023).
- •• **NEJM:** "Cirrhosis Complications" (Garcia-Tsao, 2017).

Visit: webcheatsheets.com for more education, fun resources and 10 category 1 AAPA CME credit!

© Hospital Medicine Cheat Sheets (medcheatsheets.com). For educational purposes only. Do not redistribute or sell. Neither the author nor the company is liable for realworld implications. Al was used in development